Shenzhen Salubris Pharmaceuticals Co., Ltd. (SHE:002294)
China flag China · Delayed Price · Currency is CNY
29.89
-0.36 (-1.19%)
Oct 30, 2026, 3:04 PM CST

SHE:002294 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Operating Revenue
4,7184,2163,9103,2803,4013,020
Other Revenue
136.37136.37102.7385.6781.2738.73
4,8544,3534,0123,3653,4823,058
Revenue Growth
14.15%8.48%19.22%-3.35%13.85%11.68%
Cost of Revenue
1,2691,1051,1381,0651,001811.29
Gross Profit
3,5853,2482,8742,3002,4812,247
Selling, General & Admin
2,2412,0311,7451,3021,3321,340
Research & Development
569.26539.33421.24409.19533.75357.37
Other Operating Expenses
53.5232.318.8720.246.9344.98
Operating Expenses
2,8542,6072,1901,7341,9161,743
Operating Income
731.92640.47683.83565.82565.58504.3
Interest Expense
-23.04-21.69-16.17-17.37-12.54-10.53
Interest & Investment Income
104.66105.9480.0980.94151.26181.9
Currency Exchange Gain (Loss)
-10.48-10.481.693.015.55-5.78
Other Non Operating Income (Expenses)
-42.92-0.7-1.37-0.43-5.84-7.54
EBT Excluding Unusual Items
760.14713.54748.06631.96704662.35
Impairment of Goodwill
----49.61-26.61-
Gain (Loss) on Sale of Investments
40.7836.7214.518.093.81-
Gain (Loss) on Sale of Assets
-2.19-3.03-0.15-0.48-0.18-1.3
Asset Writedown
-169.26-151.86-159.64-2.89-24.06-131.6
Other Unusual Items
60.5460.5429.7354.6856.7670.39
Pretax Income
690.01655.91632.52641.76713.73599.84
Income Tax Expense
-18.33.1227.3660.9379.3671.52
Earnings From Continuing Operations
708.31652.78605.16580.83634.37528.32
Minority Interest in Earnings
6.69-1.28-3.59-0.762.735.41
Net Income
715651.5601.57580.07637.09533.73
Net Income to Common
715651.5601.57580.07637.09533.73
Net Income Growth
6.31%8.30%3.71%-8.95%19.37%776.90%
Shares Outstanding (Basic)
1,1191,1231,1141,1161,0981,067
Shares Outstanding (Diluted)
1,1191,1231,1141,1161,0981,067
Shares Change
-0.16%0.83%-0.13%1.55%2.90%5.23%
EPS (Basic)
0.640.580.540.520.580.50
EPS (Diluted)
0.640.580.540.520.580.50
EPS Growth
6.48%7.41%3.85%-10.35%16.00%733.33%

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Free Cash Flow
74.478.34561.45168.44371.84702.48
Free Cash Flow Per Share
0.070.070.500.150.340.66
Dividend Per Share
0.5500.5500.5000.5000.5000.400
Dividend Growth
10.00%10.00%0%0%25.00%-
Gross Margin
73.86%74.61%71.64%68.34%71.26%73.47%
Operating Margin
15.08%14.71%17.04%16.81%16.24%16.49%
Profit Margin
14.73%14.97%14.99%17.24%18.30%17.45%
Free Cash Flow Margin
1.53%1.80%13.99%5.00%10.68%22.97%
EBITDA
1,1401,0291,046893.22873.67798.4
EBITDA Margin
23.48%23.64%26.08%26.54%25.09%26.11%
D&A For EBITDA
407.87388.43362.51327.4308.09294.1
EBIT
731.92640.47683.83565.82565.58504.3
EBIT Margin
15.08%14.71%17.04%16.81%16.24%16.49%
Effective Tax Rate
-0.48%4.33%9.50%11.12%11.92%
Revenue as Reported
3,8514,3534,0123,3653,4823,058